The development of mRNA based vaccines delivered in lipid nanoparticles (LNPs) has led to a surge of interest in the possible use of LNP mRNA formulation as a treatment for a range of other diseases. During this webinar, Prof. Steve Hart from the Department of Genetics & Genomic Medicine, will introduce nanoparticle technologies and the design and production of mRNA for their use in the development of therapeutics.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
13
8/2/2024
Phage display is a recombinant screening technology that involves the construction of bacteriophage libraries that express large numbers (1*10^11) of peptides or proteins as fusions to the major or minor coat proteins of bacteriophage species such as M13. Phage display is routinely used in the pharmaceutical industry to develop fully human antibodies against a range of different diseases targets, including cancer and inflammatory diseases. Dr Chris Morris, from the School of Pharmacy, presented examples of how phage display can be applied to the identification of peptide-based motifs for targeting biological structures at three different length scales – whole cells in melanoma skin cancer, individual glycan-binding proteins in human lung infections and subcellular, non-canonical DNA structures.
11
6/6/2024
This session will unravel the complexities of developing inhaled formulations of biologics for the treatment of respiratory diseases such as severe asthma, viral infections, and cystic fibrosis. In her presentation, Dr Jenny Lam from the School of Pharmacy will give an overview of the use of particle engineering techniques and formulation strategies to overcome the delivery barriers. She will also introduce the spray drying technology, a versatile and scalable particle engineering technique that has been investigated for producing dry powder formulation of biologics with good stability (avoid cold-chain logistics) and aerosolisation properties for inhalation.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments.
22
5/23/2024
Antisense oligonucleotides (AONs) can be used to alter many aspects of gene expression, from splice isoform switching to reducing, or increasing, gene expression. The retina is an accessible part of the nervous system and is an ideal paradigm to study how AONs can be used to combat neurodegeneration.
During this webinar, Prof. Mike Cheetham from the Institute of Ophthalmology will give an overview of AON design and show how they can be used as therapies for inherited retinal dystrophies (IRDs), from stem cell derived models of disease, to in vivo and clinical trials. This will exemplify the potential of AONs to treat genetic disease, and IRDs in particular.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biome
23
3/27/2024
During this webinar, Professor Stephen Moss explored the reasons behind choosing this modality and the steps involved in progressing a few hopeful ideas into something ready to inject into patients. He will also relate his own experience of this journey that resulted in the development of Magacizumab, an antibody that blocks the activity of leucine-rich a-2-glycoprotein 1, with a range of therapeutic applications.This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
29
2/7/2024
During this webinar Prof. Paul Dalby will introduce examples of the kinds of research that is undertaken in Biochemical Engineering, in collaboration with academia and industry, to streamline the development and optimisation of manufacturing processes. This will also be an opportunity to explore the use of product engineering to improve their developability. Examples will cover a range of modalities including antibodies, cell therapies and viral vectors.
This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.
35
1/10/2024
Speakers:
Prof Dan Bracewell - "Manufacturing of Exosomes"
Prof Ahad Rahim - "Lentiviral Vector Packaging"
To keep updated with activities and opportunities from the Biologics TIN, subscribe to the TINs newsletter: https://www.ucl.ac.uk/therapeutic-innovation-networks/join-community/subscribe-tins-newsletter
78
7/20/2021
The session was be hosted by Professor Paul Dalby (Biologics TIN Chair), and includes an introduction to the Biologics Therapeutic Innovation Network (TIN) and the opportunities provided through the TIN, followed by two speakers from the Biologics community at UCL:
Speakers:
Prof Steve Brocchini - Intraocular formulations of antibody-based medicines
Prof Paul Dalby - Understanding and predicting the formulation of therapeutic proteins
This event is open to all (UCL and non-UCL).
44
6/8/2021